Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $73.00 at Mizuho

Enliven Therapeutics (NASDAQ:ELVN) had its price target increased by research analysts at Mizuho from $62.00 to $73.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s price target points to a potential upside of 22.63% from the company’s current price.

Several other research analysts have also recently commented on the company. Stifel Nicolaus raised their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. JonesTrading boosted their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics has an average rating of “Moderate Buy” and an average target price of $74.50.

Enliven Therapeutics Trading Up 1.2%

Shares of ELVN stock opened at $59.53 on Tuesday. The stock has a 50 day moving average of $51.42 and a two-hundred day moving average of $41.13. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $62.32. The company has a market capitalization of $4.36 billion, a P/E ratio of -35.65 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts predict that Enliven Therapeutics will post -1.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares in the company, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the transaction, the director owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 190,831 shares of company stock worth $10,991,723 over the last three months. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth about $221,255,000. Vestal Point Capital LP grew its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Siren L.L.C. acquired a new stake in shares of Enliven Therapeutics during the first quarter worth approximately $29,252,000. Jupiter Topco LLC acquired a new stake in shares of Enliven Therapeutics during the second quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $23,007,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.